Anil Narasimha, Ph.D., CEO

April 13 | 4:45pm | Dark Horse Consulting Ballroom   

Oct. 11 | 11:30am | UBC Ballroom 

San Francisco, CA 


Mekonos is a CGT platform company building the future of cell therapies on a chip.  The company’s System on a Chip merges innovations in MEMS, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale, offering an integrated solution for advanced cell and gene therapy development from R&D through Manufacturing. Mekonos’ ex vivo delivery technology uses silicon nanoneedles to enable high efficiency cargo delivery into any cell type, including primary immune cells, iPSCs and HSCs.  The company’s nanoneedle-based delivery system — one needle, one cell — offers single-cell precision at scale and a level of consistency unachievable with conventional delivery technologies. The Mekonos platform enables unique cell engineering capabilities, including nuclear delivery, multiplexing and dose control for hyper-precise ex-vivo delivery. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions